The 2022 STOFF trainees have been selected. Congratulations, we look forward to seeing you in August.
A significant component of the STOFF program is the in-person time faculty and fellows spend together for mentorship and discussion. Based on guidance from the co-chairs, feedback from the faculty, and the current pandemic circumstances, this year’s Forum, originally scheduled for January 27-29, has been postponed to Thursday, August 18 - Saturday, August 20, 2022.

 

Society for Translational Oncology Fellows' Forum (STOFF) is an intensive 3-day workshop that brings together 25 fellows and junior faculty within 5 years of training completion from leading medical, surgical, radiation, and pediatric oncology groups and subspecialty fellowships to educate these rising stars on issues around and barriers to successful translational cancer research.

This forum is internationally acclaimed for its focused, practical, and personal approach. It provides guidance to oncology fellows and junior faculty regarding how to apply translational research findings in tumor biology to improve patient outcomes. The broad-based curriculum covers a range of topics related to new drug development.

With a faculty to student ratio of 1:1.5, trainees have unique opportunities to connect with other scientists and clinicians in translational research efforts that benefit from multidisciplinary and interprofessional investigation.

The faculty features prominent scientists, clinicians, ethicists, industry representatives, and biotech investors who serve as mentors. These distinguished leaders in cancer drug development lecture and lead discussions topics such as:

  • Preclinical and clinical evaluation
  • Validation of targets and biomarkers
  • Confirmation of mechanism of action and resistance in clinical trials
  • Racial and age-related disparities in clinical trials
  • Mechanics of grant-writing
  • Guidelines for good basic research

“Educating young oncologists in the field of clinical and translational research is an investment in the future and is likely to impact the quality of cancer patient care for years to come,” said Bruce A. Chabner (Massachusetts General Hospital/Harvard Medical School), founder the course more than two decades ago. Since then, many of the 540+ alumni have earned significant acclaim in their careers and drug development success.

After completion of this training, participants should be able to:

  • Identify the importance of translational research and define its value in clinical medicine.
  • Describe the process of drug development in oncology.
  • Apply the mechanics of grant writing and guidelines for sound research practices.
  • Establish a network of peer oncologists focused on translational research.